Genzyme Genetics Launches New Prognostic Test for Common Leukemia

Date: February 20, 2007

Westborough, MA - Genzyme Genetics recently launched its IgV_H Mutation Analysis assay for patients with chronic lymphocytic leukemia (CLL). CLL is the most prevalent form of adult leukemia, affecting approximately 120,000 people in Europe and the United States.

IgV_H is an independent prognostic marker which can be utilized to segregate patients within all stages of CLL. Studies show that CLL patients with mutations in their IgV_H gene have a longer median survival (293 months) than CLL patients without these mutations (117 months). Approximately 50 to 70 percent of patients with B-cell CLL (B-CLL) have evidence of these mutations. The National Comprehensive Cancer Network (NCCN) recommends IgV_H Mutation Analysis for patients diagnosed with CLL.

With the addition of the IgV_H Mutation Analysis assay, Genzyme has expanded its diagnostic menu for B-CLL patients. The company also offers a minimal residual disease test, which detects very low levels of disease in B-CLL patients.

About Genzyme Genetics

Genzyme Genetics is a leading, nationwide provider of high quality, complex testing services for physicians and their patients. With CLIA-certified laboratories and counseling facilities located across the U.S., Genzyme Genetics offers extensive diagnostic testing services, supported by innovative technology and a commitment to quality service and trusted information. Genzyme Genetics is a business unit of Genzyme Corporation.